Evidence map›Paper›PMID 30381302›Full record

Trial reportHaematologica2019

A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

Lionel Ades, Agnès Guerci-Bresler, Pascale Cony-Makhoul, Laurence Legros, Marie Sebert, Thorsten Braun, Jacques Delaunay, Kristell Desseaux, Sylvie Chevret, Pierre Fenaux

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Clinical update on hypomethylating agents.International journal of hematology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lionel AdesService d'Hématologie Séniors, St Louis Hospital, University Paris 7.
Agnès Guerci-BreslerHematology Department, Hopital d'Adultes du Brabois, Nancy.
Pascale Cony-MakhoulCentre Hospitalier d'Annecy.
Laurence LegrosHematology Department, CH de l'Archet, Nice.
Marie SebertService d'Hématologie Séniors, St Louis Hospital, University Paris 7.
Thorsten BraunHematologie Clinique, CHU Avicenne, Bobigny.
Jacques DelaunayDepartment of Hematology, Nantes University Hospital.
Kristell DesseauxDepartment of Statistics (DBIM), Hôpital Saint Louis University Paris 7, France.
Sylvie ChevretDepartment of Statistics (DBIM), Hôpital Saint Louis University Paris 7, France.
Pierre FenauxService d'Hématologie Séniors, St Louis Hospital, University Paris 7 pierre.fenaux@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAzacitidineFemaleHumansMaleMiddle AgedMyelodysplastic SyndromesRisk FactorsAzacitidine

Identifiers

PMID30381302
PMCPMC6442966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.